All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, August 12, 2022
Home » Blogs » BioWorld MedTech Perspectives » The new Wild West: the life sciences

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

The new Wild West: the life sciences

Oct. 30, 2014
By Mark McCarty
No Comments

Ridin' herd ain't what it used to be, is it?
Ridin' herd ain't what it used to be.

The life sciences have fostered an environment that can get pretty crazy, but let's face it: That's one of the things we like about the life sciences. Below are two stories that rival the tallest tales told of the Old West, but these two stories happen to be true stories.

Hamburg; clinical trials for Ebola

The latest outbreak of Ebola has generated a few rhetorical whoppers by elected and appointed officials. One of the weirder among them is a remark by FDA Commissioner Margaret Hamburg, who said in a recent blog at FDA Voice that the agency “strongly” supports clinical trials for Ebola vaccines and treatments.

Color me chicken, pardner, but there is no way in the world I'm going to consent to be randomized in a trial for a vaccine or a treatment for a cold-blooded killer.

However, the idea of a non-randomized trial for Ebola doesn’t make much more sense than a saddle without stirrups, either. For starters, the current outbreak will be well past done by the time any trial has a chance to make it out of the barn. Then you have to ask yourself whether the next outbreak will present a virus with the same surface proteins and other characteristics as the current outbreak. If the answer is no, any diagnostic, treatment or vaccine currently in development mightn’t lasso the critter.

Care to sink your hard-earned coin into that kind of ranch? I wouldn’t.

Cook Medical’s warning letter

Cook Medical is a big wheel in the device business, and certainly has the pockets for a top-notch compliance staff. But as we have seen in the past, even big companies with deep pockets sometimes don’t ride their herds very well.

The September 16 warning letter to Cook addressed the plant that manufactures catheters and other devices, stating that the company had identified more than 700,000 non-conforming livestock "across all device families" over a stretch of about two years. Among the problems were labels that seemed to fall apart, and a process that did not do a particularly good job of bonding catheter tips to the catheters.

There was one recall of the company's devices that took place during the period in question, the Zilver PTX stent for the peripheral vasculature. The company said in its May 2013 statement that the rate of catheter tip separation was 0.043%, which to the greenhorn sounds like a good rate.

Still, Cooke had to trash more than half a million devices due to the non-conformities, which can't have been cheap.

However innocuous these problems might have been, device makers have to understand something about Sheriff Jeff Shuren. He and the rest of the agency have no breathing room (from the media or from Congress) when it comes to problematic medical devices. If a device maker has a problem that seems a minor problem, the real question might be "would this be a problem for Johnny Law?"

If the answer is “yes” – even if it’s just a problem of optics where the townfolk are concerned – then it's a problem for the device maker, too. If you’re in the device industry, you simply cannot let wild horses run loose in your corral. Your ranch is regulated. Tightly. And please, no excuses. It’s not as if you didn’t get the flyer.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 11, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 11, 2022.
  • Amvuttra

    Alnylam’s Amvuttra rare disease drug among positive recommendations from Europe’s CHMP

    BioWorld
    Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran), a treatment for the rare disease hereditary transthyretin-mediated amyloidosis, was among medicines...
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing